Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc.
Your view on LLBO
Overview
What the company does, where it operates, and who runs it.
About Lifeline Biotechnologies, Inc.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- James D. Holmes
- Headquarters
- 1325 Airmotive Way, Reno, NV, US
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- James D. Holmes
- Headquarters
- 1325 Airmotive Way, Reno, NV, US
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases.
The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women.
It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe.
Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Lifeline Biotechnologies, Inc., and the rating behind it. LLBO last traded at $0.0004; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lifeline Biotechnologies, Inc.. Starting points for Lifeline Biotechnologies, Inc.: beta -2.04 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lifeline Biotechnologies, Inc.. Lifeline Biotechnologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lifeline Biotechnologies, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lifeline Biotechnologies, Inc.. Lifeline Biotechnologies, Inc. has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lifeline Biotechnologies, Inc. valued side by side against its closest peers. Lifeline Biotechnologies, Inc. is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Lifeline Biotechnologies, Inc., and how their positions are changing. At a $1.7M market value, institutional positions materially move Lifeline Biotechnologies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Lifeline Biotechnologies, Inc. executives and directors. Shares of Lifeline Biotechnologies, Inc. have traded between $0.0001 and $0.0013 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lifeline Biotechnologies, Inc.. Lifeline Biotechnologies, Inc. is a $1.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lifeline Biotechnologies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lifeline Biotechnologies, Inc.. Coverage tracks Lifeline Biotechnologies, Inc. within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.